Area of research
Oncology · Immunology
Research interest
Research interests include CAR-T cell therapy research, CRISPR and Genetic Engineering, Immune Cell Function and Interaction, and T-cell and B-cell Immunology.
Lung tumouroids as a testing platform for precision CAR T cell therapy
mRNA-based CAR T cell engineering: Unmodified mRNA enables high CAR expression without innate immune activation in T cells
TGFβ links EBV to multisystem inflammatory syndrome in children
Gene editing of CD3 epsilon to redirect regulatory T cells for adoptive T cell transfer
HLA matching or CRISPR editing of HLA class I/II enables engraftment and effective function of allogeneic human regulatory T cell therapy in a humanized mouse transplantation model
Generation of Regulatory T Cells From Human Memory CD4 <sup>+</sup> T Cells by Upregulation of Naked Cuticle Homolog 2
Multi-parametric profiling of IL-7-augmented GD2.CART products in a phase 1 clinical trial
Integration of <i>ζ</i>-deficient CARs into the <i>CD3</i> <i>ζ</i> gene conveys potent cytotoxicity in T and NK cells
In Vitro Transcribed mRNA Immunogenicity Induces Chemokine‐Mediated Lymphocyte Recruitment and Can Be Gradually Tailored by Uridine Modification
Effector memory–type regulatory T cells display phenotypic and functional instability
Combining different CRISPR nucleases for simultaneous knock-in and base editing prevents translocations in multiplex-edited CAR T cells
CAR NK-92 cell–mediated depletion of residual TCR+ cells for ultrapure allogeneic TCR-deleted CAR T-cell products
Integration of ζ-deficient CARs into the <i>CD3-zeta</i> gene conveys potent cytotoxicity in T and NK cells
Pharmacological interventions enhance virus-free generation of TRAC-replaced CAR T cells
Adoptive transfer of ex vivo expanded regulatory T cells improves immune cell engraftment and therapy-refractory chronic GvHD
Tacrolimus-resistant SARS-CoV-2-specific T cell products to prevent and treat severe COVID-19 in immunosuppressed patients
In vitro and in vivo evidence that the switch from calcineurin to mTOR inhibitors may be a strategy for immunosuppression in Epstein–Barr virus–associated post-transplant lymphoproliferative disorder
Cyclosporine A but Not Corticosteroids Support Efficacy of Ex Vivo Expanded, Adoptively Transferred Human Tregs in GvHD
HCoV- and SARS-CoV-2 Cross-Reactive T Cells in CVID Patients
The TreaT-Assay: A Novel Urine-Derived Donor Kidney Cell-Based Assay for Prediction of Kidney Transplantation Outcome